$MYL

This $140M contract to Chartwell RX LLC for essential antibiotics signals robust government demand for pharmaceutical preparedness, directly benefiting generic drug manufacturers like Teva Pharmaceutical Industries Ltd. ($TEVA) and Viatris Inc. ($MYL) through increased market stability and potential supply chain opportunities.

The Advancing Education on Biosimilars Act of 2021 increases awareness and adoption of biosimilar drugs, directly benefiting biosimilar manufacturers and increasing competition for branded biologic drug companies. This legislation expands the market for biosimilars and drives down healthcare costs.